This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

First Published Papers On IMRIS Suites Report Positive Results

WINNIPEG, Sept. 26, 2011 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that the first published results on the early clinical experiences at hospitals using the IMRIS system, highlight a number of positive findings for procedures and patient outcomes resulting from utilization of the intraoperative MRI capabilities available in IMRIS suites.

The studies which were conducted at hospitals in three different countries each concluded that the IMRIS system can be safely integrated into neurosurgical workflows and enable intraoperative modification of surgical strategy in a range of neurosurgical procedures.

The studies included 180 patients treated from April 2008 to July 2009 at the Washington University School of Medicine in St. Louis, Missouri, USA (Chicoine MR., et al); 45 patients treated between July 2008 and July 2009 at PLA 301 Hospital in Beijing, China, ( Xiaolei Chen, et al); and 120 patients who underwent procedures between January 2009 and November 2009 at University of Calgary Foothills Hospital in Calgary, Alberta, Canada, ( Michael J. Lang, et al).

Highlights include:

  • In 41% of all cases in the Washington University School of Medicine study and in 48.9% of all cases included in the study at PLA 301 Hospital, the surgeon modified the surgical procedure based upon the intraoperative MR imaging information provided by the IMRIS suite.
  • Gross/near total tumor resection was achieved in 93% of patients with gliomas in the Washington University School of Medicine study, compared with 65% for procedures that did not utilize the intraoperative MR imaging capabilities in the same timeframe.
  • Gross/near total tumor resection was achieved in 76.9% of the pituitary adenoma procedures in the PLA 301 Hospital preliminary clinical experience which compared with 38.5% of the procedures having achieved gross/near total tumor resection prior to the intraoperative MR imaging.
  • From clinical experience with 120 patients, the University of Calgary Foothills Hospital study found that intraoperative imaging resulted in modification to surgery in a substantial number of patients and concluded that intraoperative imaging at 3.0T is safe, reliable and capable of directing image guided surgery with exceptional image quality.

Links to Abstracts for the studies referenced in this news release are available at the U.S. National Library of Medicine National Institutes of Health database website: www.pubmed.gov.

Globally, more than 6,000 procedures have now been completed in IMRIS suites which are designed to provide timely imaging information to assist clinicians in making better decisions for improved patient outcomes.  IMRIS suites allow a high field MR scanner to move into an operating room on demand before, during and after procedures without moving the patient.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,230.73 +98.03 0.54%
S&P 500 2,109.86 +5.36 0.25%
NASDAQ 4,988.5180 +24.9910 0.50%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs